

Philip Connell, M.D.

The University of Chicago
Department of Radiation and Cellular Oncology
University of Chicago
5758 South Maryland Av., MC 9006
Chicago IL, 60637
Office: (773) 834-8119
Fax: (773) 834-7179
Email: pconnell@radonc.uchospitals.edu
Web page: <http://www.uchospitals.edu/physicians/philip-connell.html>

ACADEMIC APPOINTMENTS

2010- Associate Professor, Radiation & Cellular Oncology, University of Chicago
2003- 10 Assistant Professor, Radiation & Cellular Oncology, University of Chicago
2001- 03 Instructor, Radiation & Cellular Oncology, University of Chicago

Program and Center Appointments

2005- Pharmacogenomics and Experimental Therapeutics, program member
2006-10 Residency Program Director, Radiation Oncology, University of Chicago

ACADEMIC TRAINING

1987- 91 B.S., Tufts University, Medford, MA
1991-95 M.D., New York Medical College, Valhalla, NY
1995-96 Internship, Internal Medicine, St. Vincent's Hospital, New York, NY
1996-00 Residency, Radiation Oncology, University of Chicago Hospitals
1999-01 N.I.H. Research Fellow, Dep. Radiation and Cellular Oncology, University of Chicago

BOARD CERTIFICATION AND LICENSURE

2000 Board Certification: American Board of Radiology (Radiation Oncology)
2010 Re-certification: American Board of Radiology (Radiation Oncology)
Current Permanent IL state medical license

SCHOLARSHIP

(a) Peer-reviewed publications in the primary literature, exclusive of abstracts:

1. Mundt AJ, **Connell PP**, Campbell T, Hwang JH, Rotmensch J, Waggoner S: Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy. *Gynecol Oncol* 71(2): 151-158, 1998. (see editorial)
2. **Connell PP**, Rotmensch J, Waggoner SE, Mundt AJ: Race and clinical outcome in endometrial carcinoma. *Obstet Gynecol* 94 (5 Pt 1): 713-720, 1999.
3. Calvin D, **Connell PP**, Rotmensch J, Waggoner S, Mundt AJ: Surgery and postoperative radiation therapy in Stage II endometrial carcinoma. *Am J Clin Oncol* 22(4): 338-343, 1999.

4. **Connell PP**, Rotmensch J, Waggoner S, Mundt AJ: The significance of adnexal involvement in endometrial carcinoma. *Gynecol Oncol* 74(1): 74-79, 1999.
5. Weiss MF, **Connell PP**, Waggoner S, Rotmensch J, Mundt AJ: External pelvic radiation therapy in Stage IC endometrial carcinoma. *Obstet Gynecol* 93(4): 599-602, 1999.
6. Mundt AJ, **Connell PP**, Mansur DB: What is the optimal treatment volume in Hodgkin's disease patients undergoing high dose chemotherapy and adjuvant radiation therapy? *Rad Oncol Invest* 7(6): 353-359, 1999.
7. **Connell PP**, Ignacio L, McBride R, Weichselbaum RR, Vijayakumar S: Caution in interpreting biochemical control rates after treatment for prostate cancer: Length of follow-up influences results. *Urology* 54(5): 875-879, 1999.
8. **Connell PP**, MacDonald RL, Mansur DB, Nicholas MK, Mundt AJ: Tumor size predicts control of benign meningiomas treated with radiotherapy. *Neurosurgery* 44(6): 1194-1199, 1999. (discussion 1199-1200)
9. Wollschlaeger K, **Connell PP**, Waggoner S, Rotmensch J, Mundt AJ: Acute problems during low dose rate brachtherapy in cervical carcinoma. *Gynecol Oncol* 76(1): 67-72, 2000.
10. Rotmensch J, **Connell PP**, Yamada D, Waggoner S, Mundt AJ: One versus two intracavitary brachytherapy applications in early-stage cervical patients undergoing definitive radiation therapy. *Gynecol Oncol* 78(1): 32-38, 2000.
11. Mundt AJ, **Connell PP**: Do conventional pathologic features lose their prognostic significance following postoperative radiation therapy in pathologic stage I-II endometrial adenocarcinoma? *Int J Cancer* 90(4): 224-230, 2000.
12. Mundt AJ, Waggoner S, Yamada D, Rotmensch J, **Connell PP**: Age as a prognostic factor for recurrence in patients with endometrial carcinoma. *Gynecol Oncol* 79(1): 79-85, 2000.
13. Tran BN, **Connell PP**, Waggoner S, Rotmensch J, Mundt AJ: Characteristics and outcome of endometrial carcinoma patients age 45 years and younger. *Am J Clin Oncol* 23(5): 476-480, 2000.
14. Castro IM, **Connell PP**, Waggoner S, Rotmensch J, Mundt AJ: Synchronous ovarian and endometrial malignancies. *Am J Clin Oncol* 23(5): 521-525, 2000.
15. Jani AB, **Connell PP**, Vesich VJ, O'Brien KM, Chen LM: Analysis of the role of adjuvant chemotherapy for invasive carcinoma of the esophagus. *Am J Clin Oncol* 23(6):554-558, 2000.
16. **Connell PP**, Ignacio L, Haraf D, Awan AM, Halpern H, Abdalla I, Nautiyal J, Jani AB, Weichselbaum RR, Vijayakumar S: Equivalent racial outcome following conformal radiotherapy for prostate cancer: a single departmental experience. *J Clin Oncol* 19(1): 54-61, 2000.
17. Mundt AJ, Murphy KT, Rotmensch J, Waggoner SE, Yamada D, **Connell PP**: Surgery and postoperative radiation therapy in FIGO stage IIIC endometrial carcinoma. *Int J Radiat Oncol Biol Phys* 50(5): 1154-60, 2001.
18. Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada D, **Connell PP**: Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant

chemotherapy alone: Implications for adjuvant radiation therapy. *Int J Radiat Oncol Biol Phys* 50(5): 1145-53, 2001.

19. Ashman JB, **Connell PP**, Yamada D, Rotmensch J, Waggoner SE, Mundt AJ: Outcome of endometrial carcinoma patients with involvement of the uterine serosa. *Gynecol Oncol* 82(2): 338-43, 2001.

20. Jani AB, Basu A, Abdalla I, **Connell PP**, Krauz L, Vijayakumar S: Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer. *Am J Clin Oncol* 26(4):382-5, 2003.

21. **Connell PP**, Siddiqui N, Hoffman S, Kuang A, Khatipov EA, Weichselbaum RR, Bishop DK: A hot spot for RAD51C interactions revealed by a peptide that sensitizes cells to cisplatin. *Cancer Res* 64(9):3002-5, 2004.

22. Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, **Connell PP**, Kwon OH, Jani AB, Heimann R: Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. *Int J Radiat Oncol Biol Phys* 59(2):445-53, 2004.

23. **Connell PP**, Kron SJ, Weichselbaum RR: Relevance and irrelevance of DNA damage response to radiotherapy. *DNA Repair* 3(8-9): 1245-1251, 2004.

24. **Connell PP**, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW: Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. *Int J Oncol* 28(5): 1113-1119, 2006.

25. Shaikh AY, Haraf DJ, Salama JK, Salgia R, Hoffman PC, Ferguson MK, **Connell PP**: Chemotherapy and High Dose Radiotherapy Followed by Resection for Locally Advanced Non-Small Cell Lung Cancers. *Am J Clin Oncol* 30(3): 258-63, 2007.

26. Seiwert TY, **Connell PP**, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE: A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. *Clin Cancer Res* 13(2 Pt 1):515-22, 2007.

27. Knab B, **Connell PP**: Radiotherapy for pediatric brain tumors: when and how. *Expert Rev Anticancer Ther* 7(12 Suppl):S69-77, 2007.

28. Jayathilaka K, Sheridan SD, Bold T, Bochenska K, Logan HL, Weichselbaum RR, Bishop DK, **Connell PP**: A chemical compound that stimulates the human homologous recombination protein RAD51. *Proc Nat Acad Sci USA* 105(41):15848-53, 2008. (See coverage in SciBX (Science-Business eXchange at <http://www.nature.com/scibx/journal/v1/n38/pdf/scibx.2008.916.pdf>)

29. **Connell PP**, Hellman S: American Association of Cancer Research Centennial Series: Advances in Radiotherapy and Implications for the Next Century. *Cancer Res* 69(2):383-92, 2009.

30. MacDermed DM, Miller LL, Peabody TD, Simon MA, Luu HH, Haydon RC, Montag AG, Undevia SD, **Connell PP**: Primary Tumor Necrosis Predicts Distant Control in Locally Advanced Soft Tissue Sarcomas Following Preoperative Concurrent Chemoradiotherapy. *Int J Radiat Oncol Biol Phys* 76(4):1147-53, 2010

31. Shumway D, Corbin K, Salgia R, Hoffman P, Villaflor V, Malik RM, Haraf DJ, Vigneswaren WT, Shaikh AY, **Connell PP**, Ferguson MK, Salama JK: Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. *Lung Cancer*. 74(3):446-50, 2011
32. Cosnefroy O, Tocco A, Lesbats P, Thierry S, Calmels C, Wiktorowicz T, Reigadas S, Kwon Y, De Cian A, Desfarges S, Bonot P, San Filippo J, Litvak S, Le Cam E, Rethwilm A, Fleury H, **Connell PP**, Sung P, Delelis O, Andréola ML, Parissi V: Stimulation of hRAD51 nucleofilament restricts HIV-1 integration in vitro and in infected cells. *J Virol*. 86(1):513-26, 2011
33. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, **Connell PP**, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR: Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. *Cancer*, 2011.
34. Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, **Connell PP**, Vokes EE, Weichselbaum RR, Salama JK: Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer. *J Thorac Oncol*. 7(2):376-81, 2012
35. Budke B, Logan HL, Kalin JH, Zelivianskaia AS, Cameron McGuire W, Miller LL, Stark JM, Kozikowski AP, Bishop DK, **Connell PP**: RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. *Nucleic Acids Res* 40(15):7347-57, 2012
36. Budke B, Kalin JH, Pawlowski M, Zelivianskaia AS, Wu M, Kozikowski AP, **Connell PP**: An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. *J Med Chem* 56(1):254-63, 2013
37. Spraker MB, Bair E, Bair R, **Connell PP**, Mahmood U, Koshy M: An Analysis of Patient Characteristics and Clinical Outcomes in Primary Pulmonary Sarcoma. *J Thorac Oncol*. 8(2):147-51, 2013
38. Liauw SL, **Connell PP**, Weichselbaum RR: New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology. *Sci Transl Med* 5(173):173sr2, 2013 (** co-first author)
39. Budke B, Chan YL, Bishop DK, **Connell PP**: Real-time solution measurement of RAD51- and RecA-mediated strand assimilation without background annealing. *Nucleic Acids Res*. 41(13):e130, 2013
40. Pitroda SP, Pashtan IM, Logan HL, Budke B, Darga TE, Weichselbaum RR, **Connell PP**: DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. *Sci Transl Med*, 6(229):229ra42, 2014.
41. Mason JM, Logan HL, Budke B, Wu M, Pawlowski M, Kozikowski AP, Bishop DK, **Connell PP**: The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors. *Cancer Research* 2014 (published in 'on-line first' version currently)

(b) Non-peer-reviewed original articles

1. **Connell PP**, Weichselbaum RR: Gene Therapy: the challenges of translating laboratory research into clinical practice. *J Clin Oncol* 21(12):2230-1, 2003.
2. Martin RW, **Connell PP**, Bishop DK. The Yin and Yang of treating BRCA-deficient tumors. *Cell* 132(6):919-20, 2008.
3. **Connell PP**, Weichselbaum RR: A downside to apoptosis in cancer therapy? *Nat Med* 17(7):780-2, 2011.
4. **Connell PP**, Weichselbaum RR: A small molecule derived from a natural product that mitigates radiation injury. *Proc Nat Acad Sci USA* 110(46):18355-6, 2013

(c) Books (as editor):

1. Brown C, Rini B, **Connell PP**: *Holland-Frei Manual of Cancer Medicine*. Hamilton, Ontario: BC Decker, 1st ed, 2005. (multiple chapters additionally co-authored by Connell PP in this textbook)

(d) Book chapters:

1. **Connell PP**, Martel MK, Hellman S: Principles of Cancer Management: Radiation Therapy. In DeVita V, Hellman S, Rosenberg S. *Cancer: Principles and practice of oncology*. Philadelphia: Lippincott Raven, 8th ed, 2004
2. Salama J, **Connell PP**: Pediatric Tumors: Rhabdomyosarcoma. In Mundt A, Roeske J: *Intensity Modulated Radiation Therapy: A Clinical Perspective*. Hamilton, Ontario: BC Decker, 2005.
3. **Connell PP**, Nanda R: Fundamentals of DNA Damage and Repair. In Stadler W: *Cancer Biology Review- A Case Based Approach*. New York: Demos Medical Publishing, 2014.

(e) Ongoing clinical trials

Serving as principle investigator:

None

Serving as co-investigator:

Active cooperative group trials:

ACOSOG trials: Z4051

Children's Oncology Group trials: AHOD0831, ARST08P1, ANBL00B1, ACNS0822, ACNS0821, AHEP0731, AEWS1031, ANBL09P1, AHOD003, ACNS0121, ALTE04N1, ACNS0331, ALTE03N1, ACNS0221, AHOD0431, ANBL0032, Head Start III, ACNS0232, ARST0531, AHOD04B1, AALL0434, ACNS0332, ANBL0531, ANBL0532, P9641, AALL1131

CALGB trials: 80803, 31102, 30610

RTOG trials: 0436

Childhood Cancer Survivor Study (CCSS): on-going database collection effort

Active internal trials at University of Chicago:

- 1) Long Term Database Collection and Analysis of Patients with Limited Metastatic Disease Treated with Hypofractionated Radiotherapy
- 2) Long Term Database Collection for Lymphoma
- 3) University of Chicago Pediatric Hematology/Oncology Registry Protocol
- 4) A Study of Dose Escalation of Hypofractionated Radiation Therapy in Patients with Metastatic Cancer (IRB# 13619B)
- 5) A Long Term Investigation of Radiation Treatment in Lung Cancer Patients Investigating Radiation Pneumonitis Genetics
- 6) Investigation of Gene Expression Profiles in Primary and Metastatic tumors in Patients with Surgically Resected Lung Metastases

(f) Research manuscripts in the peer-review process

1. Mason JM, Dusad K, Grubb J, Weichselbaum RR, **Connell PP**, Bishop DK: The RAD54 family translocases counter genotoxic effects of RAD51 overexpression in human tumor cells. (revised manuscript recently resubmitted to *Journal of Cell Biology*)

(g) Patents (allowed and pending)

1. US Utility Application No. 12/671,147 (allowed), filing date 7/28/2008: Methods and Compositions for Modulating Rad51 and Homologous Recombination. **Philip P. Connell**, Douglas K. Bishop, Ralph R. Weichselbaum.
2. US Provisional Application No. 61/731,982 (pending), filing date 11/30/2012: Methods and Compositions Involving Rad51 Inhibitors. Brian Budke, Jay H. Kalin, Michal Pawlowski, Alan P. Kozikowski, **Philip P. Connell**.
3. US Provisional Application No. 61/881,331 (pending), filing date 9/23/2013: Methods and Compositions Relating to Cancer Therapy with DNA Damaging Agents. Sean P. Pitroda, Ralph R. Weichselbaum, **Philip P. Connell**
4. U.S. Patent Application No. 14/074,395 (pending), filing date 11/7/2013: Methods and Compositions for Modulating Rad51 and Homologous Recombination. **Philip P. Connell**, Douglas K. Bishop, Ralph R. Weichselbaum.

FUNDING

(a) Past:

Fanconi Anemia Research Fund Connell (PI) 10/1/09 – 9/30/11
Title: Restoration of homologous recombination in Fanconi anemia
Main goals: To use existing RAD51-stimulatory compounds to reverse Fanconi anemia phenotypes.

1R21CA124557-01A1 Connell (PI) 7/1/07 – 6/30/09
NIH/NCI (no cost extension to 6/30/10)
Title: Inhibition of Recombination DNA Repair in Pancreatic Cancer Cells
Main goals: To develop novel inhibitors of homologous recombinational DNA repair, for the sensitization of pancreatic cancer cells to radiation and chemotherapeutic drugs.

Loan Repayment Program Connell (PI) 7/1/04 – 10/30/09

Role: Co-investigator/clinical scientist

(b) Current:

NIH/NCI: 5R01CA142642-02. PI: P. Connell. Title: "RAD51 inhibitors for chemotherapy and radiation therapy." Total direct costs: \$2,246,721. Annual salary recovery or effort: 15%. Project period: 03/16/10 - 01/31/15

(c) Pending:

Competing renewal application for NIH/NCI: 5R01CA142642-02. PI: P. Connell. Title: "RAD51 inhibitors for chemotherapy and radiation therapy." Total direct costs: \$2,650,618. Annual salary recovery or effort: 15%. Notification expected: July 2014. Projected dates: 02/01/15 - 01/31/20

HONORS, PRIZES, AND AWARDS

2004, 2005	American Society for Therapeutic Radiology and Oncology Junior Faculty Fellowship Award
2003	Samuel Hellman Teaching Award
2001	Cancer Research Foundation Young Investigator Grant Award
1999	Roentgen Society Research Award
1999	American Brachytherapy Society Research Award
1997	American Society of Clinical Oncology Merit Award

INVITED SPEAKING

2014	Invited speaker, NRG Oncology, Semiannual Meeting, Chicago
2014	Grand rounds speaker, Dep. of Orthopedics, University of Chicago
2011	Invited speaker, Kluver Symposium on Neuro-Oncology, Gleacher Center, Chicago
2010	Invited speaker, International Workshop on Radiation Damage to DNA, Atlanta
2010	Invited speaker, Radiation Oncology Faculty Seminar Series: University of Chicago
2009	Grand rounds speaker, Section of Orthopedics University of Chicago
2008	Invited speaker, Translational Seminar Series, University of Chicago CRC
2008	Invited speaker, Gordon Research Conference: Radiation Oncology, Ventura, CA
2007	Grand rounds speaker, University of Chicago Pediatric Oncology Educational Series
2007	Invited speaker, University of Chicago Breast Cancer SPORE Seminar Series
2007	Research Seminar, FASEB Summer Research Conference: Genetic Recombination & Genome Rearrangements, Snowmass Village, CO
2007	Invited speaker, Advances in Neuro-Oncology Symposium, Gleacher Center, Chicago
2005	Invited speaker, University of Chicago Thoracic Oncology Retreat
2003	Invited speaker, Bioscience Division, Argonne National Laboratory, Argonne, IL

INVITED, ELECTED, OR APPOINTED EXTRAMURAL SERVICE

2014	Reviewer for NIH Special Emphasis Panel ZCA1 PCRB-A (A1) S
2011	Reviewer for NIH Special Emphasis Panel ZRG1 OTC-Y 02 M
2010	Reviewer for NIH Scientific Review Group CONC (Clinical Oncology)
2010	Reviewer for NIH Special Emphasis Panel ZRG1 DTCS-A
2009	Reviewer for NIH Special Emphasis Panel ZRG VH-D
Various	Manuscript reviewer for various journals including Cancer Research, Nucleic Acids Research, International Journal of Radiation Oncology Biology Physics, Molecular Cancer Research, Journal of Clinical Oncology

PROFESSIONAL SOCIETIES

Elected:

N/A

General membership:

The Alliance for Clinical Trials in Oncology

The American Society of Therapeutic Radiology and Oncology (ASTRO)

Children's Oncology Group (COG)

Chicago Medical Society

Illinois State Medical Society

EDUCATIONAL CONTRIBUTIONS

Graduate programs (Ph.D.):

2005- Annual lecture: "Fundamentals of Radiation Oncology" in CANCER BIOLOGY 1: HUMAN CANCER PRESENTATION AND MODELING (director: Mark Lingen)

Pritzker School of Medicine (M.D.):

(a) Didactic

N/A

(b) Clinical

2001- Patient care including medical students during 12 month per year (2-3 days/wk)

Graduate medical education (residency and clinical fellowships):

(a) Didactic

2001- Annual lecture on pediatric radiotherapy as part of the Rad/Onc Residency

2001- Annual lecture on soft tissue sarcomas as part of the Rad/Onc Residency

2008- Annual lecture on radiotherapy as part of the Pediatric Oncology Fellowship

2001- Preceptor for weekly case presentation series with Rad/Onc residents

2001- Preceptor for weekly treatment management series with residents and faculty

(b) Clinical

2001- Patient care with 1 resident during 12 month of each year (2-3 days/wk), focusing primarily on pediatric malignancies and adult sarcomas.

Continuing medical education (for resident and faculty):

2010- Course Director: Radiation Oncology Faculty Research Discussion Series

Research trainees:

(a) Undergraduate (B.A., B.S.)

2003-2005 Tyler Bold, undergraduate degree from University of Illinois, after my lab he completed an MD/PhD program at New York University

2005- 2007 Krishanthi Jayathilaka, undergraduate degree from University of Minnesota, after my lab she completed an MD at Loyola University

- 2006- 2007 Katie Bochenska, undergraduate degree from Northwestern, after my lab she completed an MD at University of Illinois at Chicago
- 2010- 2011 Cameron McGuire, undergraduate degree from Northwestern, currently in medical school (MD/MPH) at Tulane
- 2011- 2012 Anna Zelivianskaia, undergraduate degree from University of Chicago, currently in medical school at University of Illinois at Chicago
- 2011- Megan Wu, University of Chicago, currently a junior in The College

(b) Medical Student

- 2007-2009 Luke Miller, Pritzker School of Medicine. He was awarded Calvin Fentress Fellowship and first prize in Senior Scientific Session for his work. Luke is currently a radiation oncology resident at Loyola.

(c) Postdoctoral (Ph.D.)

- 2010- Brian Budke, PhD. Currently a research post-doctoral fellow in my lab

(d) Radiation Oncology Residents

- 2005-06 Arif Shaikh, MD. He performed clinical research project on lung cancer outcomes. He now shares a joint appointment in our department and is centered at NorthShore University Health System.
- 2006-07 Brian Knab MD. He performed clinical research project on evolving treatment modalities in pediatric brain tumors.
- 2008-09 Dhara MacDermed,MD. She performed clinical research project on sarcoma outcomes during residency. Following which she began a translational research fellowship at The Scripps Research Institute.
- 2011- Sean Pitroda, MD. He performed genomics-based studies that yielded a paper in *Science Translational Medicine*. He is currently completing residency in our department

CLINICAL

- 2001- I treat all of the patients with **pediatric malignancies** and **adult sarcomas** that require radiotherapy in our medical center, and I represent Rad/Onc at both multidisciplinary tumor conferences. I additionally treat a portion of the adult patients with **thoracic cancers**.

SERVICE

University of Chicago

Committee membership:

- 2005- Rad/Onc Residency Educational Committee

2005- Rad/Onc Physics Residency Educational Committee
2006-2012 Clinical Trials Review Committee (CTRC)
2010-2011 Interviewer of medical school applicants, Pritzker School of Medicine
2012 Institute for Translational Medicine, ad hoc reviewer for grant proposals
2012 BSD Committee on Appointments and Promotions (COAP), ad hoc reviewer
2013 BSD Committee on Reappointment of Assistant Professors (COROAP), member

Leadership:

2007- Chair, University of Chicago Rad/Onc Faculty Recruitment Committee

Other:

2012- Appeared in newspaper and posted banner advertisements for University of Chicago Medicine